Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
暂无分享,去创建一个
W. Wilson | M. Raffeld | S. Rosenberg | R. Morgan | M. Stetler-Stevenson | J. Janik | M. Dudley | Debbie-Ann N. Nathan | S. Feldman | J. Kochenderfer | I. Maric | B. Lanier | W. Wilson
[1] M. Kalos,et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Sadelain,et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] M. Brenner,et al. Immunotherapy of human cancers using gene modified T lymphocytes. , 2009, Current gene therapy.
[4] W. Wilson,et al. Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.
[5] D. Campana,et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[7] Michel Sadelain,et al. The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.
[8] Hao Liu,et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.
[9] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[10] S. Sleijfer,et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo , 2007, Cancer Immunology, Immunotherapy.
[11] David D. Smith,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.
[12] B. Blom,et al. Development of human lymphoid cells. , 2006, Annual review of immunology.
[13] M. Smyth,et al. Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.
[14] V. V. D. van der Velden,et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts , 2004, Cytometry. Part B, Clinical cytometry.
[15] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[16] A. Órfão,et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL , 1999, Leukemia.
[17] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Rosenberg,et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.
[19] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] F. Lemoine,et al. Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development. , 1993, Blood.
[21] H. Asaoku,et al. Phenotypic difference of normal plasma cells from mature myeloma cells. , 1993, Blood.
[22] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] Arthur Weiss,et al. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.
[24] A. Fauci,et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. , 1988, Blood.
[25] G. Marti,et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. , 1983, Journal of immunology.